1-{2-[(2,3-Dimethylphenyl)amino]phenyl}ethan-1-one | 2241142-06-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-{2-[(2,3-Dimethylphenyl)amino]phenyl}ethan-1-one
• 英文别名: 1-[2-(2,3-dimethylanilino)phenyl]ethanone
• CAS: 2241142-06-1
• 化学式: C₁₆H₁₇NO
• 分子量: 239.31
• InChiKey: VBIZUKRIAWKHQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
  申请人：KANDULA Mahesh

  公开号：US20150148306A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Type II diabetes, Type I diabetes, insulin resistance, cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, macular adema, arthritis, osteoarthritis, rheumatoid arthritis, inflammatory bowel syndrome, neudegeneration, Alzheimer's disease, Huntington's disease, Ulcerative colitis, Crohn's disease, Multiple Sclerosis, muscular dystropthy, metabolic syndrome, fatty liver, bone diseases, inflammatory diseases.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗炎症的方法可以制成口服、颊部、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射剂。这些组合物可用于治疗II型糖尿病、I型糖尿病、胰岛素抵抗、心血管疾病、心律失常、动脉粥样硬化、冠状动脉疾病、高三酰甘油血症、脂质代谢异常、视网膜病变、肾病、神经病变、黄斑水肿、关节炎、骨关节炎、类风湿性关节炎、炎症性肠病、神经退行性疾病、阿尔茨海默病、亨廷顿病、溃疡性结肠炎、克罗恩病、多发性硬化症、肌肉萎缩症、代谢综合征、脂肪肝、骨疾病、炎症性疾病的治疗。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018115984A1

  公开（公告）日：2018-06-28

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.

  本公开提供了化合物I的结构或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些化合物可以制备成药物组合物。药物组合物可以制备成口服、静脉注射、喷雾、注射、含片、溶液、糖浆、小包装、经皮给药或注射的药物。这些组合物可用于治疗炎症或其相关并发症。
• HYDROGELATORS COMPRISING D-AMINO ACIDS
  申请人：BRANDEIS UNIVERSITY

  公开号：US20150306232A1

  公开（公告）日：2015-10-29

  Described herein are compounds comprising an oligopeptide and a non-steroidal antiinflammatory agent. The compounds self-assemble into supramolecular hydrogels and can be used as topical treatments for inflammatory conditions, such as osteoarthritis. Also described herein are oligopeptides compounds made from D-amino acid residues that form supramolecular hydrogels. The compounds may be functionalized with active agents, such as anticancer therapeutic agents, antiinflammatory agents, or imaging agents, therefore providing new mechanisms for delivery of active agents.

  本文描述了包含寡肽和非甾体抗炎药物的化合物。这些化合物自组装成超分子水凝胶，并可用作局部治疗炎症疾病，如骨关节炎。本文还描述了由D-氨基酸残基制成的寡肽化合物，形成超分子水凝胶。这些化合物可与活性剂（如抗癌治疗剂、抗炎剂或成像剂）功能化，因此提供了新的活性剂传递机制。
• [EN] NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE<br/>[FR] NOUVEAUX COMPOSÉS DÉRIVÉS DE TAURINE, PROCESSUS DE PRÉPARATION DE CES COMPOSÉS ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：EMS SA

  公开号：WO2009124371A9

  公开（公告）日：2010-12-02
• Small Molecule Inhibitors of PDZ Interactions
  申请人：BELMARES MICHAEL P.

  公开号：US20080227684A1

  公开（公告）日：2008-09-18

  The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.